INT

International Isotopes showed sequential growth for the third quarter of 2011, according to filings with the Securities and Exchange Commission earlier this week, adding up to what the company said is its strongest nine-month revenue performance in company history. However, INIS continues to run a net loss while it waits for further financing and NRC license approval of its uranium de-conversion and fluorine extraction facility. Revenue for the third quarter of 2011 was $2.2 million, up 25 percent from the $1.7 million INIS reported for the same period in 2010, and revenue for the nine months of 2011 was $7.2 million, up 66 percent from the $4.4 million in the same period in 2010. But INIS’ net loss for the third quarter of 2011 was $4.8 million, up 176 percent compared to the $1.8 million in net loss reported for the third quarter in 2010. INIS said that R&D costs incurred for continued planning and licensing of the uranium de-conversion facility increased by $750,232 for the nine-month period ended September 30, 2011 to $4.2 million, as compared to $3.5 million for the same period in 2010.